Malignant Pleural Mesothelioma—An Update

References

• Carbone M, Kratzke RA, Testa JR. The pathogenesis of meso-thelioma. Semin Oncol. 2002; 29: 2–17.
   PubMed Web of Science ®Google Scholar
• Bielefeldt-Ohmann H, Jarnicki AG, Fitzpatrick DR. Molecular pathobiology and immunology of malignant mesothelioma. J Pathol. 1996; 178: 369–78.
   PubMed Web of Science ®Google Scholar
• Manning CB, Vallyathan V. Mossman BT. Diseases caused by asbestos: mechanisms of injury and disease development. Int Immunopharmacol. 2002; 2: 191–200.
   Google Scholar
• Rizzo P, Bocchetta M, Powers A, et al. SV40 and the pathogen-esis of mesothelioma. Semin Cancer Biol. 2001; 11: 63–71.
   PubMedGoogle Scholar
• Roushdy-Hammady I, Siegel J, Emri S, Testa JR, Carbone M. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet. 2001;357 (9254): 444–5.
   PubMed Web of Science ®Google Scholar
• O'Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer. 2001; 85: 473–83.
   PubMed Web of Science ®Google Scholar
• Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothe-lioma and asbestos exposure in the North West Cape Province. Br J Ind Med. 1960; 17: 260–71.
   PubMedGoogle Scholar
• Britton M. The epidemiology of mesothelioma. Semin Oncol. 2002; 29: 18–25.
   PubMed Web of Science ®Google Scholar
• Price B. Analysis of current trends in United States mesothe-lioma incidence. Am J Epidemiol. 1997; 145: 211–8.
   PubMed Web of Science ®Google Scholar
• Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer. 1999; 79: 666–72.
   PubMed Web of Science ®Google Scholar
• Nicholson WJ. The carcinogenicity of chrysotile asbestos-a review. Ind Health. 2001; 39: 57–64.
   PubMed Web of Science ®Google Scholar
• Statement on malignant mesothelioma in the United King-dom. Thorax. 2001; 56: 250–65.
   Google Scholar
• Sugarbaker DJ, Garcia JP, Richards WG, et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann Surg. 1996; 224: 288–94; discussion 294-6.
   Google Scholar
• Steele JP. Prognostic factors in mesothelioma. Semin Oncol. 2002; 29: 36–40.
   PubMed Web of Science ®Google Scholar
• Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA, O'Byrne KJ. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax. 2000; 55: 731–5.
   PubMed Web of Science ®Google Scholar
• Metintas M, Metintas S, Ucgun I, et al. Prognostic factors in dif-fuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics. Respir Med. 2001; 95: 829–35.
   PubMed Web of Science ®Google Scholar
• Calavrezos A, Koschel G, Husselmann H, et al. Malignant mesothelioma of the pleura. A prospective therapeutic study of 132 patients from 1981-1985. Kiln Wochenschr. 1988; 66: 607–13.
   Google Scholar
• Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998; 113: 723–31.
   PubMed Web of Science ®Google Scholar
• Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998; 16: 145–52.
   PubMed Web of Science ®Google Scholar
• Edwards JG, Cox G, Andi A, et al. Angiogenesis is an inde-pendent prognostic factor in malignant mesothelioma. Br J Cancer. 2001; 85: 863–8.
   PubMed Web of Science ®Google Scholar
• Edwards JG, Faux SP, Plummer SM, et al. Cycloo3cygenase-2 expression is a novel prognostic factor in malignant mesothe-lioma. Clin Cancer Res. 2002; 8: 1857-62.
   Google Scholar
• Ordonez NG. Immunohistochemical diagnosis of epithelioid mesotheliomas: a critical review of old markers, new markers. Hum Pathol. 2002; 33: 953–67.
   PubMed Web of Science ®Google Scholar
• Abutaily AS, Addis BJ, Roche WR. Immunohistochemistry in the distinction between malignant mesothelioma and pul-monary adenocarcinoma: a critical evaluation of new antibod-ies. J Clin Pathol. 2002; 55: 662–8
   PubMed Web of Science ®Google Scholar
• Boraschi P, Neri S, Braccini G, Gigoni R, Leoncini B, Perri G. Magnetic resonance appearance of asbestos-related benign and malignant pleural diseases. Scand J Work Environ Health. 1999; 25: 18–23.
   PubMed Web of Science ®Google Scholar
• Knuuttila A, Kivisaari L, Kivisaari A, Palomaki M, Tervahartiala P, Mattson K Evaluation of pleural disease using MR and CT. With special reference to malignant pleural mesothelioma. Acta Radiol. 2001; 42: 502–7.
   Google Scholar
• Marom EM, Erasmus JJ, Pass HI, Patz EF Jr. The role of imag-ing in malignant pleural mesothelioma. Semin Oncol. 2002; 29: 26–35.
   PubMed Web of Science ®Google Scholar
• Heelan RT, Rusch VW, Begg CB, Panicek DM, Caravelli JF, Eisen C. Staging of malignant pleural mesothelioma: compari-son of CT and MR imaging. AJR Am J Roentgenol. 1999; 172: 1039–47.
   PubMed Web of Science ®Google Scholar
• Gerbaudo VH, Sugarbaker DJ, Britz-Cunningham S, Di Carl MF, Mauceri C, Treves ST. Assessment of malignant pleural mesothelioma with (18)F-FDG dual-head gamma-camera coin-cidence imaging: comparison with histopathology. J Nucl Med. 2002; 43: 1144–9.
   PubMed Web of Science ®Google Scholar
• Carretta A, Landoni C, Melloni G, et al. 18-FDG positron emission tomography in the evaluation of malignant pleural diseases-a pilot study. Eur J Cardiothorac Surg. 2000; 17: 377–83.
   PubMed Web of Science ®Google Scholar
• Schneider DB, Clary-Macy C, Challa S, et al. Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2000; 120: 128–33.
   PubMed Web of Science ®Google Scholar
• Zubeldia J, Abou-Zied M, Nabi H. 11. Evaluation of patients with known mesothelioma with 18Filuorodeoxyglucose and PET. Comparison with computed tomography. Clin Positron Imaging. 2000; 3: 165.
   Google Scholar
• Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med. 1999; 40: 1241–5.
   PubMed Web of Science ®Google Scholar
• Adams RF, Gray W, Davies RJ, Gleeson FV. Percutaneous image-guided cutting needle biopsy of the pleura in the diagnosis of malignant mesothelioma. Chest. 2001; 120: 1798–802.
   PubMed Web of Science ®Google Scholar
• Butchart EG, Ashcroft T, Barnsley WC, Holden MR Pleurop-neumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax. 1976; 31: 15–24.
   Google Scholar
• Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection mar-gins, extrapleural nodal status, and cell type determine post-operative long-term survival in trimodality therapy of malig-nant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999; 117: 54–63; discussion 63-5.
   PubMed Web of Science ®Google Scholar
• Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest. 1995; 108: 1122–8.
   Google Scholar
• Baas P. Chemotherapy for malignant mesothelioma: from dox-orubicin to vinorelbine. Semin Oncol. 2002; 29: 62–9.
   PubMed Web of Science ®Google Scholar
• Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma. A review. J Clin Oncol. 1996; 14: 1007–17.
   PubMed Web of Science ®Google Scholar
• Ryan CW, Herndon J, Vogelzang NJ. A review of chemotherapy trials for malignant mesothelioma. Chest. 1998;113(1 suppl): 66S-73S.
   PubMed Web of Science ®Google Scholar
• Singhal 5, Kaiser LR. Malignant mesothelioma: options for management. Surg Clin North Am. 2002; 82: 797-831.
   Google Scholar
• Berghrnans T, Paesmans M, Lalami Y, et al. Activity of chemo-therapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer. 2002; 38: 111–21.
   PubMed Web of Science ®Google Scholar
• Steele JP, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM. Phase II study of vinorelbine in patients with malig-nant pleural mesotheliorna. J Clin Oncol. 2000; 18: 3912–7.
   PubMed Web of Science ®Google Scholar
• Kindler HL, van Meerbeeck JP. The role of Gemcitabine in the treatment of malignant mesothelioma. Semin Oncol. 2002; 29: 70–6.
   PubMed Web of Science ®Google Scholar
• Kindler HL, Millard F, Herndon JE 2nd, Vogelzang NJ, Suzuki Y, Green MR. Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B. Lung Cancer. 2001; 31: 311–7.
   Google Scholar
• Byrne MJ, Davidson JA, Musk AW, et al. Cisplatin and Gemc-itabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol. 1999; 17: 25–30.
   PubMed Web of Science ®Google Scholar
• Nowak AK, Byrne MJ, Williamson R, et al. A multicentre phase II study of Cisplatin and Gemcitabine for malignant mesothe-lioma. Br J Cancer. 2002; 87: 491–6.
   PubMed Web of Science ®Google Scholar
• van Haarst JM, Baas P, Manegold C, et al. Multicentre phase II study of Gemcitabine and Cisplatin in malignant pleural mesothelioma. Br J Cancer. 2002; 86: 342–5.
   PubMed Web of Science ®Google Scholar
• Middleton GW, Smith IE, O'Brien ME, et al. Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cis-platin) chemotherapy in malignant mesothelioma. Ann Oncol. 1998; 9: 269–73.
   PubMed Web of Science ®Google Scholar
• Calvert H, Bunn PA Jr. Future directions in the development of pemetrexed. Semin Oncol. 2002;29(2 suppl 5):54-61.
   Google Scholar
• Curtin NJ, Hughes AN. Pemetrexed disodium, a novel antifo-late with multiple targets. Lancet Oncol. 2001; 2: 298–306.
   PubMed Web of Science ®Google Scholar
• Norman R Pemetrexed disodium (Eli Lilly). Curr Opin Inves-tig Drugs. 2001; 2: 1611–22.
   Google Scholar
• Vogelzang NJ, Rusthoven J, Paoletti P, et al. Phase III single-blinded study of pemetrexed + Cisplatin vs Cisplatin alone in chemonaive patients with malignant pleural mesothelioma. Proceedings of the 38th meeting of the American Society of Clinical Oncology, 2002. Abstract number 5.
   Google Scholar
• Bueno R, Appasani K, Mercer H, Lester S, Sugarbaker D. The alpha folate receptor is highly activated in malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001; 121: 225–33.
   PubMed Web of Science ®Google Scholar
• Bogliolo GV, Lerza R, Bottino GB, et al. Regional pharmacoki-netic selectivity of intrapleural Cisplatin. Ear J Cancer. 1991; 27: 839–42.
   PubMed Web of Science ®Google Scholar
• Rusch V, Saltz L, Venkatraman E, et al. A phase II trial of pleurectomy/decortication followed by intrapleural and sys-temic chemotherapy for malignant pleural mesothelioma. J Clin Oncol. 1994; 12: 1156–63
   PubMed Web of Science ®Google Scholar
• Shoji T, Tanaka F, Yanagihara K, Inui K, Wada H. Phase II study of repeated intrapleural chemotherapy using implantable access system for management of malignant pleural effusion. Chest. 2002; 121: 821–4.
   PubMed Web of Science ®Google Scholar
• Omasa M, Hirata T, Shoji T, et al. A case of repetitive intra-pleu-ral cancer chemotherapy using INFUSE-A-PORT for malignant mesothelioma. Thorac Cardiovasc Surg. 2001; 49: 233–5.
   PubMed Web of Science ®Google Scholar
• Matsuzaki Y, Shibata K, Yoshioka M, et al. Intrapleural perfu-sion hyperthermo-chemotherapy for malignant pleural dis-semination and effusion. Ann Thorac Surg. 1995; 59: 127–31.
   PubMed Web of Science ®Google Scholar
• de Bree E, van Ruth S, Baas P, et al. Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. Chest. 2002; 121: 480–7.
   PubMed Web of Science ®Google Scholar
• Yellin A, Simansky DA, Paley M, Refaely Y. Hyperthermic pleu-ral perfusion with Cisplatin: early clinical experience. Cancer. 2001; 92: 2197–203.
   PubMed Web of Science ®Google Scholar
• Ratto GB, Civalleri D, Esposito M, et al. Pleural space perfusion with Cisplatin in the multimodality treatment of malignant mesothelioma: a feasibility and pharmacokinetic study. J Thorac Cardiovasc Surg. 1999; 117: 759–65.
   PubMed Web of Science ®Google Scholar
• Bakhshandeh A, Bruns I, Traynor A, et al. Ifosfamide, Carbo-platin and Etoposide combined with 41.82C whole body hyper-thermia for malignant pleural mesothelioma. Lung Cancer. 2003; 39: 339-45.
   Google Scholar
• Kestenholtz PB, Taverna C, Schneiter D, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy (EPP) and adjuvant radiotherapy for malignant mesothelioma (MPM). Proceedings of the American Society of Clinical Oncology 2002; Abstract no. 1338.
   Google Scholar
• Waller DA. The role of surgery in the diagnosis and treatment of malignant pleural mesothelioma. Curr Opin Oncol. 2003; 15: 139–43.
   PubMed Web of Science ®Google Scholar
• Benko I, Molnar TF, Horvath OR Palliative treatment of malignant pleural effusions by video-assisted thoracoscopic sur-gery. Acta Chir Hung. 1999; 38: 131–3.
   PubMedGoogle Scholar
• Furedi A, Kecskes L, Geher P, Kiss B. Video-assisted thoraco-scopic pleurodesis for malignant pleural effusions. Acta Chir Hung. 1999; 38: 155–7.
   PubMedGoogle Scholar
• Waller DA, Morritt GN, Forty J. Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion. Chest. 1995; 107: 1454–6.
   PubMed Web of Science ®Google Scholar
• Grossebner MW, Arifi AA, Goddard M, Ritchie AJ. Mesothe-lioma-VATS biopsy and lung mobilization improves diagnosis and palliation. Eur J Cardiothorac Surg. 1999; 16: 619–23.
   PubMed Web of Science ®Google Scholar
• Martin-Ucar AE, Edwards JG, Rengajaran A, Muller S, Waller DA. Palliative surgical debulking in malignant mesothelioma. Predictors of survival and symptom control. Eur J Cardiothorac Surg. 2001; 20: 1117–21.
   Web of Science ®Google Scholar
• Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. J Thorac Cardiovasc Surg. 1991; 102: 1–9.
   PubMed Web of Science ®Google Scholar
• Sugarbaker DJ, Mentzer SJ, Strauss G. Extrapleural pneu-monectomy in the treatment of malignant pleural mesothe-lioma. Ann Thorac Surg. 1992; 54: 941–6.
   PubMed Web of Science ®Google Scholar
• Rusch VW. Indications for pneumonectomy. Extrapleural pneumonectomy. Chest Surg Clin North Am. 1999; 9: 327–38
   PubMedGoogle Scholar
• Pass HI, Kranda K, Temeck BK, Feuerstein I, Steinberg SM. Surgically debulked malignant pleural mesothelioma: results and prognostic factors. Ann Surg Oncol. 1997; 4: 215–22.
   PubMed Web of Science ®Google Scholar
• Conlon KC, Rusch VW, Gillern S. Laparoscopy: an important tool in the staging of malignant pleural mesothelioma. Ann Surg Oncol. 1996; 3: 489–94.
   PubMed Web of Science ®Google Scholar
• Zellos LS, Sugarbaker DJ. Multiniodality treatment of diffuse malignant pleural mesothelioma. Semin Oncol. 2002; 29: 41–50.
   PubMed Web of Science ®Google Scholar
• Sugarbaker DJ, Norberto B, Swanson SJ. Extrapleural pneu-monectomy in the setting of multimodality therapy for diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 1997; 9: 373–82.
   PubMedGoogle Scholar
• Rusch VW. Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma. Chest. 1993;103(4 suppl) :382S-384S.
   Google Scholar
• Rusch VW. Pleurectomy/decortication in the setting of multi-modality treatment for diffuse malignant pleural mesothe-lioma. Semin Thorac Cardiovasc Surg. 1997; 9: 367–72.
   PubMedGoogle Scholar
• Carmichael J, Degraff WG, Gamson J, et al. Radiation sensitiv-ity of human lung cancer cell lines. Eur J Cancer Clin Oncol. 1989; 25: 527–34.
   PubMedGoogle Scholar
• Steele JP, Rudd RM. Malignant mesothelioma: predictors of prognosis and clinical trials. Thorax. 2000; 55: 725–6.
   PubMed Web of Science ®Google Scholar
• Kutcher GJ, Kestler C, Greenblatt D, Brenner H, Hilaris BS, Non i D. Technique for external beam treatment for mesothe-lioma. Intl Radiat Oncol Biol Phys. 1987; 13: 1747–52.
   PubMed Web of Science ®Google Scholar
• Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest. 1995; 108: 754–8.
   PubMed Web of Science ®Google Scholar
• Senan S. Indications and limitations of radiotherapy in malig-nant pleural mesothelioma. Curr Opin Oncol. 2003; 15: 144–7.
   PubMed Web of Science ®Google Scholar
• Baldini EH, Recht A, Strauss GM, et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Arm Thorac Surg. 1997; 63: 334–8.
   PubMed Web of Science ®Google Scholar
• Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radi-ation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001; 122: 788–95.
   PubMed Web of Science ®Google Scholar
• Lee TT, Everett DL, Shu HK, et al. Radical pleurectorny/decor-tication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2002; 124: 1183–9.
   PubMed Web of Science ®Google Scholar
• Raben A, Mychalczak B. Brachytherapy for non-small cell lung cancer and selected neoplasms of the chest. Chest. 1997;112(4 suppl):276S-286S.
   Google Scholar
• Hilaris BS, Non i D, Kwong E, Kutcher GJ, Martini N. Pleurec-tomy and intraoperative brachytherapy and postoperative radi-ation in the treatment of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 1984; 10: 325–31.
   PubMedGoogle Scholar
• Derycke S, De Gersem WR, Van Duyse BB, De Neve WC. Con-formal radiotherapy of stage III non-small cell lung cancer: a class solution involving non-coplanar intensity-modulated beams. Int J Radiat Oncol Biol Phys. 1998; 41: 771–7.
   PubMed Web of Science ®Google Scholar
• 'Brugmans MJ, van der Horst A, Lebesque JV, Mijnheer BJ. Beam intensity modulation to reduce the field sizes for confor-mal irradiation of lung tumors: a dosimetric study. Int J Radiat Oncol Biol Phys. 1999; 43: 893–904.
   Google Scholar
• Meeks SL, Buatti JM, Bova FJ, Friedman WA, Mendenhall WM, Zlotecki RA. Potential clinical efficacy of intensity-modulated conformal therapy. Int J Radiat Oncol Biol Phys. 1998; 40: 483–95.
   PubMed Web of Science ®Google Scholar
• Stevens C. IMRT after resection of pleural mesothelioma. 6th Meeting of the International Mesotheliorna Interest Group, 1-4 December 2002; Abstract no. 29.
   Google Scholar
• Ahamad A, Stevens CW, Smythe WR, et al. Intensity modulated radiation therapy: A novel approach to the management of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2003; 55: 768–75.
   Google Scholar
• Forster KM, Smythe WR, Starkschall G, et al. Intensity modu-lated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: Clinical implemen-tation. Int J Radiat Oncol Biol Phys. 2003; 55: 606–16.
   PubMed Web of Science ®Google Scholar
• Rusch VW, Venkatraman ES. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgi-cally. Ann Thorac Surg. 1999; 68: 1799–804.
   PubMed Web of Science ®Google Scholar
• Maggi G, Casadio C, Cianci R, Rena O, Ruffini E. Trimodality management of malignant pleural mesothelioma. Eur J Car-diothorac Surg. 2001 19: 346-50.
   Google Scholar
• Sterman DH, Kaiser LR, Albelda SM. Advances in the treatment of malignant pleural mesothelioma. Chest. 1999; 116: 504–20.
   PubMed Web of Science ®Google Scholar
• Pass HI, Pogrebniak H. Photodynamic therapy for thoracic malignancies. Semin Surg Oncol. 1992; 8: 217–25.
   PubMedGoogle Scholar
• Pass HI, Temeck BK, Kranda K, et al. Phase III randomized trial of surgery with or without intraoperative photodynamic ther-apy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol. 1997; 4: 628–33.
   PubMed Web of Science ®Google Scholar
• Moskal TL, Dougherty TJ, Urschel JD, et al. Operation and photodynamic therapy for pleural mesothelioma: 6-year follow-up. Ann Thorac Surg. 1998; 66: 1128-33.
   Google Scholar
• Baas P, Murrer L, Zoetmulder FA, et al. Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies. Br J Cancer. 1997; 76: 819–26.
   PubMed Web of Science ®Google Scholar
• Luketich JD, Westkaemper J, Sommers KE, Ferson PF, Keenan RJ, Landreneau RJ. Bronchoesophagopleural fistula after pho-todynamic therapy for malignant mesothelioma. Ann Thorac Surg. 1996; 62: 283–4.
   PubMed Web of Science ®Google Scholar
• Temeck BK, Pass HI. Esophagopleural fistula: a complication of photodynamic therapy. South Med J. 1995; 88: 271–4.
   PubMed Web of Science ®Google Scholar
• Hahn SM, Smith RP, Friedberg J. Photodynamic therapy for mesothelioma. Curr Treat Options Oncol. 2001; 2: 375–83.
   PubMedGoogle Scholar
• Krueger T, Alterman HJ, Mettler D, Scholl B, Magnusson L, Ris HB. Experimental photodynamic therapy for malignant pleu-ral mesothelioma with pegylated mTHPC. Lasers Surg Med. 2003; 32: 61–8.
   PubMed Web of Science ®Google Scholar
• Schwarzenberger P, Byrne P, Kolls JK. Immunotherapy-based treatment strategies for malignant mesothelioma. Curr Opin Mol Ther. 1999; 1: 104–11.
   PubMedGoogle Scholar
• O'Byrne KJ, Dalgleish AG, Browning MJ, Steward WP, Harris AL. The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer. 2000; 36: 151–69.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick DR, Peroni DJ, Bielefeldt-Ohmann H. The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma. Am J Respir Cell Mol Biol. 1995; 12: 455–60.
   PubMed Web of Science ®Google Scholar
• Lew F, Tsang P, Holland JF, Warner N, Selikoff U, Bekesi JG. High frequency of immune dysfunctions in asbestos workers and in patients with malignant mesothelioma. J Clin Immunol. 1986; 6: 225–33.
   PubMed Web of Science ®Google Scholar
• Castagneto B, Zai S, Mutti L, et al. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleu-ral mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients. Lung Cancer. 2001; 31: 303–10.
   PubMed Web of Science ®Google Scholar
• Goey SH, Eggermont AM, Punt CJ, et al. Intrapleural adminis-tration of interleukin 2 in pleural mesothelioma: a phase I-II study. Br J Cancer. 1995; 72: 1283–8.
   PubMed Web of Science ®Google Scholar
• Astoul P, Bertault-Peres P, Durand A, Catalin J, Vignal F, Boutin C. Pharmacokinetics of intrapleural recombinant interleukin-2 in immunotherapy for malignant pleural effusion. Cancer. 1994; 73: 308–13.
   PubMed Web of Science ®Google Scholar
• Nowak AK, Lake RA, Kindler HL, Robinson BW. New approaches for mesothelioma: biologics, vaccines, gene ther-apy, and other novel agents. Semin Oncol. 2002; 29: 82–96.
   PubMed Web of Science ®Google Scholar
• Caminschi I, Venetsanakos E, Leong CC, Garlepp MJ, Scott B, Robinson BW. Interleukin-12 induces an effective antitumor response in malignant mesothelioma. Am J Respir Cell Mol Biol. 1998; 19: 738–46.
   PubMed Web of Science ®Google Scholar
• Caminschi I, Venetsanakos E, Leong CC, Garlepp MJ, Robin-son BW, Scott B. Cytokine gene therapy of mesothelioma. Immune and antitumor effects of transfected interleukin-12. Am J Respir Cell Mol Biol. 1999; 21: 347–56.
   Google Scholar
• Ohnuma T, Szrajer L, Holland JF, Kurimoto M, Minowada J. Effects of natural interferon alpha, natural tumor necrosis factor alpha and their combination on human mesothelioma xenografts in nude mice. Cancer Immunol Immunothe.r 1993; 36: 31–6.
   PubMed Web of Science ®Google Scholar
• Stain TC, Swank AJ, Kruit WH, Stoter G, Eggermont AM. Intrapleural administration of tumour necrosis factor-alpha (TNFalpha) in patients with mesothelioma: cytokine patterns and acute-phase protein response. Eur J Clin Invest. 2000; 30: 336–43.
   PubMed Web of Science ®Google Scholar
• Bowman RV, Manning LS, Davis MR, Robinson BW. Capacity of tumor necrosis factor to augment lymphocyte-mediated tumor cell lysis of malignant mesothelioma. Clin Immunol Immunopathol. 1991; 58: 80–91.
   PubMedGoogle Scholar
• Martinet N, Charles T, Vaillant P, Vignaud JM, Lambert J, Mar-tinet Y. Characterization of a tumor necrosis factor-alpha inhibitor activity in cancer patients. Am J Respir Cell Mol Biol. 1992; 6: 510–5.
   PubMed Web of Science ®Google Scholar
• Christmas TI, Manning LS, Davis MR, Robinson BW, Garlepp MJ. HLA antigen expression and malignant mesothelioma. Am J Respir Cell Mol Biol. 1991; 5: 213–20.
   PubMed Web of Science ®Google Scholar
• Boutin C, Viallat JR, Van Zandwijk N, et al. Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma. Cancer. 1991; 67: 2033–7.
   PubMed Web of Science ®Google Scholar
• Boutin C, Nussbaum E, Monnet I, et al. Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer. 1994; 74: 2460–7.
   PubMed Web of Science ®Google Scholar
• Davidson JA, Musk AW, Wood BR, et al. Intralesional cytokine therapy in cancer: a pilot study of GM-CSF infusion in mesothe-lioma. J Immunother. 1998; 21: 389–98.
   PubMed Web of Science ®Google Scholar
• Monnet I, Breau JL, Moro D, et al. Intrapleural infusion of acti-vated macrophages and gamma-interferon in malignant pleu-ral mesothelioma: a phase II study. Chest. 2002; 121: 1921–7.
   PubMed Web of Science ®Google Scholar
• Halme M, Knuuttila A, Vehmas T, et al. High-dose methotrex-ate in combination with interferons in the treatment of malig-nant pleural mesothelioma. Br J Cancer. 1999; 80: 1781–5.
   PubMed Web of Science ®Google Scholar
• Metintas M, Ozdemir N, Ucgun I, et al. Cisplatin, mitomycin, and interferon-alpha2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma. Chest. 1999; 116: 391–8.
   PubMed Web of Science ®Google Scholar
• O'Reilly EM, Ilson DH, Saltz LB, Heelan R, Martin L, Kelsen DR A phase II trial of interferon alpha-2a and Carboplatin in patients with advanced malignant mesothelioma. Cancer Invest. 1999; 17: 195–200.
   PubMed Web of Science ®Google Scholar
• Purohit A, Moreau L, Dietemann A, etal. Weekly systemic com-bination of Cisplatin and interferon alpha 2a in diffuse malig-nant pleural mesothelioma. Lung Cancer. 1998; 22: 119–25.
   PubMed Web of Science ®Google Scholar
• Parra HS, Tixi L, Latteri F, et al. Combined regimen of Cis-platin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multi-center trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP). Cancer. 2001; 92: 650–6.
   PubMed Web of Science ®Google Scholar
• Pass HW, Temeck BK, Kranda K, Steinberg SM, Pass HI. A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction. Ann Surg Oncol. 1995; 2: 214–20.
   PubMed Web of Science ®Google Scholar
• Xiao GH, Beeser A, Chernoff J, Testa JR p21-activated kinase links Rac/Cdc42 signaling to merlin. J Biol Chem. 2002; 277: 883–6.
   PubMed Web of Science ®Google Scholar
• Xio S, Li D, Vijg J, Sugarbaker DJ, Corson JM, Fletcher JA. Codeletion of p15 and p16 in primary malignant mesothe-lioma. Oncogene. 1995; 11: 511–5.
   PubMed Web of Science ®Google Scholar
• Wong L, Zhou J, Anderson D, Kratzke RA. Inactivation of p16(INK4a) expression in malignant mesothelioma by methy-lation. Lung Cancer. 2002; 38: 131–6.
   PubMed Web of Science ®Google Scholar
• Frizelle SP, Grim J, Zhou J, etal. Re-expression of pl6INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene. 1998; 16: 3087-95.
   Google Scholar
• Frizelle SP, Rubins JB, Zhou JX, Curiel DT, Kratzke RA. Gene therapy of established mesothelioma xenografts with recombi-nant pl6INK4a adenovirus. Cancer Gene Then 2000; 7: 1421–5.
   PubMed Web of Science ®Google Scholar
• Yang CT, You L, Yeh CC, et al. Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. J Nail Cancer Inst. 2000; 92: 636–41.
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Haenel T, Himbeck R, et al. Replication-restricted Vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. Cancer Gene Then 2000; 7: 663–70.
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Nelson D, Loh S, et al. The immune anti-tumor effects of GM-CSF and B7-1 gene transfection are enhanced by surgical debulking of tumor. Cancer Gene Ther. 2001; 8: 580–8.
   PubMed Web of Science ®Google Scholar
• Gattacceca F, Pilatte Y, Billard C, et al. Ad-IFN gamma induces antiproliferative and antitumoral responses in malignant mesothelioma. Clin Cancer Res. 2002; 8: 3298–304.
   PubMed Web of Science ®Google Scholar
• Odaka M, Wiewrodt R, DeLong P, et al. Analysis of the immunologic response generated by Ad.IFN-beta during suc-cessful intraperitoneal tumor gene therapy. Molec Then 2002; 6: 210–8.
   PubMed Web of Science ®Google Scholar
• Smythe WR, Hwang HC, Elshami AA, etal. Treatment of exper-imental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann Surg. 1995; 222: 78–86.
   PubMed Web of Science ®Google Scholar
• Hwang HC, Smythe WR, Elshami AA, et al. Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am J Respir Cell Mol Biol. 1995; 13: 7–16.
   PubMed Web of Science ®Google Scholar
• Esandi MC, van Someren GD, Vincent AJ, et al. Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene. Gene Ther. 1997; 4: 280–7.
   PubMed Web of Science ®Google Scholar
• Sterman DH, Kaiser LR, Albelda SM. Gene therapy for malig-nant pleural mesothelioma. Hematol Oncol Clin North Am. 1998; 12: 553–68.
   PubMed Web of Science ®Google Scholar
• Sterman DH, Treat J, Litzky LA, et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene ther-apy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Then 1998; 9: 1083–92.
   PubMed Web of Science ®Google Scholar
• Lanuti M, Gao GP, Force SD, et al. Evaluation of an E1E4-deleted adenovirus expressing the herpes simplex thymidine kinase suicide gene in cancer gene therapy. Hum Gene Then 1999; 10: 463–75.
   PubMed Web of Science ®Google Scholar
• Sterman DH, Molnar-Kimber K, Iyengar T, et al. A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma. Cancer Gene Ther. 2000; 7: 1511–8.
   PubMed Web of Science ®Google Scholar
• Lambright ES, Force SD, Lanuti ME, et al. Efficacy of repeated adenoviral suicide gene therapy in a localized murine tumor model. Ann Thorac Surg. 2000; 70: 1865–70; discussion 1870-1.
   PubMed Web of Science ®Google Scholar
• Inase N, Miyake S. Yoshizawa Y. Calretinin promoter for suicide gene expression in malignant mesothelioma. Anticancer Res. 2001;21(2A):1111-4.
   Google Scholar
• Schwarzenberger P, Lei D, Freeman SM, et al. Antitumor activ-ity with the HSV-tk-gene-modified cell line PA-1-STK in malig-nant mesothelioma. Am J Respir Cell Mol Biol. 1998; 19: 333–7.
   PubMed Web of Science ®Google Scholar
• Schwarzenberger P, Harrison L, Weinacker A, et al. The treat-ment of malignant mesothelioma with a gene modified cancer cell line: a phase I study. Hum Gene Then 1998; 9: 2641–9.
   PubMed Web of Science ®Google Scholar
• Harrison LH, Jr., Schwarzenberger PO, Byrne PS, Marrogi AJ, Kolls JK, McCarthy KE. Gene-modified PAl-STK cells home to tumor sites in patients with malignant pleural mesothelioma. Ann Thorac Surg. 2000; 70: 407–11.
   PubMed Web of Science ®Google Scholar
• Xia C, Xu Z, Yuan X, et al. Induction of apoptosis in mesothe-lioma cells by antisurvivin oligonucleotides. Mol Cancer Then 2002; 1: 687–94
   PubMed Web of Science ®Google Scholar
• Smythe WR, Mohuiddin I, Ozveran M, Cao XX. Antisense ther-apy for malignant mesothelioma with oligonucleoddes target-ing the bcl-xl gene product. J Thorac Cardiovasc Surg. 2002; 123: 1191–8.
   PubMed Web of Science ®Google Scholar
• Yacyshyn BR, Chey WY, GoffJ, et al. Double blind, placebo con-trolled trial of the remission inducing + steroid sparing prop-erties of an ICAM-1 antisense oligodeoxynucleotide, ali-caforsen (ISIS 2302), in active steroid dependant Crohn's disease. Gut. 2002; 51: 30–6.
   Google Scholar
• Maksymowych WP, Blackburn WD Jr, Tami JA, Shanahan WR Jr. A randomised, placebo controlled trial of an antisense oligodeoxynucleotide to intracellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis. J Rheumatol. 2002; 29: 447–53.
   PubMed Web of Science ®Google Scholar
• Cripps MC, Figueredo AT, Oza AM, et al. Phase II randomised study of ISIS 3521 + ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study. Clin Cancer Res. 2002; 8: 2188-92.
   Google Scholar
• Chi RN, Gleave ME, Klasa R, et al. A phase I dose-finding study of combined treatment with an antisense Bc1-2 oligonucleotide (Genasense) + mitoxantrone in patients with metastatic hor-mone refractory prostate cancer. Clin Cancer Res. 2001; 7: 3920–7.
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Reyno L, Venner PM, et al. A randomised phase II + pharmacokinetic study of the antisense oligonucleotides ISIS 3521 + ISIS 5132 in patients with hormone refractory prostate cancer. Clin Cancer Res. 2002; 8: 2530–5.
   PubMed Web of Science ®Google Scholar
• Marcucci G, Byrd JC, Dai G, et al. Phase I + pharmacodynamic studies of G3139, a Bc1-2 antisense oligonucleotide, in combi-nation with chemotherapy in refractory or relapsed acute leukaemia. Blood. 2003; 101: 425–32.
   PubMed Web of Science ®Google Scholar
• Konig J, Tolnay E, Wiethege T, Muller K. Co-expression of vas-cular endothelial growth factor and its receptor fit-1 in malig-nant pleural mesothelioma. Respiration. 2000; 67: 36–40.
   PubMed Web of Science ®Google Scholar
• Dempke W, Rie C, Grothey A, Schmoll HJ. Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol. 2001; 127: 411-7.
   Google Scholar
• Ferrara N. Role of vascular endothelial growth factor in physi-ologic and pathologic angiogenesis: therapeutic implications. Semin Oncol. 2002;29(6 suppl 16):10-4.
   Google Scholar
• Jain RE. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol. 2002;29(6 suppl 16):3-9.
   Google Scholar
• Haspel HC, Scicli GM, McMahon G, Scicli AG. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the rnicrovascular endothelial cell spheroid model of angiogenesis. Microvasc Res. 2002; 63: 304–15.
   PubMed Web of Science ®Google Scholar
• Rosen LS. Angiogenesis inhibition in solid tumors. Cancer J. 2001;7 Suppl 3:S120–S128.
   PubMedGoogle Scholar
• Manley PW, Martiny-Baron G, Schlaeppi JM, Wood JM. Thera-pies directed at vascular endothelial growth factor. Expert Opin Investig Drugs. 2002; 11: 1715–36.
   PubMed Web of Science ®Google Scholar
• Kuenen BC, Rosen L, Smit EF, et al. Dose-finding and pharma-cokinetic study of Cisplatin, Gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol. 2002; 20: 1657-67.
   Google Scholar
• Marx GM, Steer CB, Harper P, Pavlakis N, Rix& 0, Khayat D. Unexpected serious toxicity with chemotherapy and antiangio-genic combinations: time to take stock! J Clin Oncol. 2002; 20: 1446–8.
   Google Scholar
• Bass P, Haringhuizen A, Custers F, Boogerd W, van Zandwijk N. Thalidomide in malignant pleural mesothelioma: results of a phase II study. Proceedings of the 6th meeting of the Interna-tional Mesothelioma Interest Group 2002. Abstract no. 13.
   Google Scholar
• Pavlakis N, Abraham R, Williams G, Harvie R, Bell D, Wheeler H. Thalidomide alone and incombination with Cisplatin/Gem-citabine chemotherapy for malignant mesothelioma: Results from two parallel phase II studies in progress. Proceedings of the 6th meeting of the International Mesothelioma Interest Group 2002. Abstract no. 20.
   Google Scholar
• Janne PA, Taffaro ML, Salgia R, Johnson BE. Inhibition of epi-dermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res. 2002; 62: 5242–7.
   PubMed Web of Science ®Google Scholar
• Kim TE, Murren JR. Erlotinib OSI/Roche/Genentech. Curr Opin Investig Drugs. 2002; 3: 1385–95.
   PubMedGoogle Scholar
• Betsholtz C, Karlsson L, Lindahl P. Developmental roles of platelet-derived growth factors. Bioessays. 2001; 23: 494–507.
   PubMed Web of Science ®Google Scholar
• George D. Platelet-derived growth factor receptors: a thera-peutic target in solid tumors. Semin Oncol. 2001;28(5 suppl 17):27-33.
   Google Scholar
• Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999; 79: 1283–316.
   PubMed Web of Science ®Google Scholar
• Stice LL, Vaziri C, Faller DV. Regulation of platelet-derived growth factor signaling by activated p21Ras. Front Biosci 1999; 4: D72–D86.
   PubMedGoogle Scholar
• Pogrebniak HW, Lubensky IA, Pass HI. Differential expression of platelet derived growth factor-beta in malignant mesothe-lioma: a clue to future therapies? Surg Oncol. 1993; 2: 235–40.
   Google Scholar
• Tomek S, Emri S, Krejcy K, Manegold C. Chemotherapy for malignant pleural mesothelioma: Past results and recent devel-opments. Br J Cancer. 2003; 88: 167–74.
   PubMed Web of Science ®Google Scholar
• Tomek S, Manegold C. Chemotherapy for malignant pleural mesothelioma. Curr Opin Oncol. 2003; 15: 148–56.
   PubMed Web of Science ®Google Scholar